Collectively, our findings suggest an important role of the Sohlh1/SFRP1/Wnt/β‐catenin pathway in regulating GSLC stemness and differentiation, suggesting potential therapeutic targets for glioma. The gene discussed is SFRP1; the disease is central nervous system cancer.